Markets US
Novo's shares surged 6% as Wegovy pill sales exceeded expectations, driving the Danish drugmaker to revise its full-year growth outlook to a range of negative 2% to 2%.
Novo reported quarterly earnings ahead of expectations on Wednesday, driven by Wegovy pill sales of 5.4 billion Danish kroner ($750 million), surpassing analyst forecasts of 4.5 billion kroner. The company raised its full-year adjusted revenue and operating profit growth outlook to negative 2% to 2% at constant exchange rates, up from previous estimates of negative 6% to flat. Q3 sales reached 79.2 billion kroner ($11.9 billion), up 4% year-on-year, while adjusted operating profit (EBIT) hit 31.7 billion kroner, exceeding analyst expectations of 28.6 billion kroner. Wegovy and Ozempic sales totaled 20.4 billion kroner and 29.7 billion kroner, respectively, both above forecasts. Novo CEO Mike Doustdar reported 80% U.S. market share for Wegovy despite fierce competition from Eli Lilly.
The results underscore Novo's reliance on Wegovy to counter Lilly's dominance in the GLP-1 market, though the revised growth outlook reflects cautious optimism amid pricing uncertainties and competition. Launching Cagri Sema, a next-gen GLP-1 drug, could shift the landscape but faces skepticism over its commercial viability. Analysts warn of long-term pricing risks and Novo's lack of a clear Wegovy successor in its pipeline, which could erode market share.
Investors and shareholders benefit from the share price surge, while competitors like Eli Lilly face pressure from Novo's strong performance. CFO Karsten Munk Knudsen, who will leave by year-end, faces scrutiny over strategic decisions. Opportunities include expanding Wegovy into eight markets and leveraging Cagri Sema to treat obesity-linked diseases beyond weight loss. However, Novo's recovery hinges on balancing growth with pricing challenges and maintaining its competitive edge against Lilly.
Unresolved issues include the CFO's departure, Cagri Sema's viability, and the broader market's response to GLP-1 drug pricing. Novo's ability to sustain its momentum will depend on its execution of these strategic priorities.
CFO Karsten Munk Knudsen will step down by year-end, with Luigi La Corte set to take over. Novo plans to launch Cagri Sema, while Eli Lilly also revised its full-year outlook upward.
Novo's strong Wegovy sales signal a rebound, but sustaining growth hinges on Cagri Sema's success and navigating pricing uncertainties.
Topics: Pharmaceuticals, Biotechnology, Drug Pricing, GLP-1 Drugs, Novo Nordisk, Eli Lilly, Market Share, Earnings Report
#NovoPharma #WegovySales #GLP1Market #CagriSema #DrugPricing #EarningsReport
Source: CNBC
Post a Comment
Post a Comment